Alkermes plc. price to free cash flow ALKS

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: 33.0×
8-year median: 33.1×
Against its 8-year history: 50th; percentile: 0 is its lowest day, 100 its highest
8-year range: 8.9× to 337×
Peer median: 50.9×

Alkermes plc.'s price to free cash flow is 33.0× as of Oct 23, 2026.

That is below its 8-year median of 33.1×, close to the middle of its last 8 years.

Over that time it ranged from 8.9× in Jul 2025 to 337× in Jan 2023.

The median for 10 large drugmakers of a similar size is 50.9×.

Price to free cash flow over time

median 33.1×

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	33.0×	9.5×	41.4×
2025	9.6×	8.9×	16.2×
2024	15.2×	10.0×	21.1×
2023	18.2×	15.6×	337×
2022	304×	31.2×	304×
2021	33.2×	31.2×	85.6×
2020	214×	196×	220×
2019	231×	45.8×	237×
2018	n/m a value too high to mean anything
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	116×	47.5×	118×
2013	48.3×	34.3×	88.0×
2012	72.8×	72.8×	79.5×

Against its peers

Companies in Drug Manufacturers - General nearest Alkermes plc.'s size, closest first, today.

Company	Price to free cash flow
ALKSAlkermes plc.	33.0×
AMRXAmneal Pharmaceuticals	50.9×
TGTXTG Therapeutics	477×
LGNDLigand Pharmaceuticals	46.0×
KNSAKiniksa Pharmaceuticals International	32.7×
PTGXProtagonist Therapeutics	68.6×
CORTCorcept Therapeutics	86.8×
BMRNBiomarin Pharmaceutical	14.7×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	100×
JAZZJazz Pharmaceuticals	8.7×
Peer median	50.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Alkermes plc.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.